Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945951 | 0.84 | HTT (0.41) | KDM4EBCHEACHEFFAR1L3MBTL1 | |
| SCHEMBL8228423 | 0.84 | KDM1A (0.47) | BCHEACHEFFAR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL24935997 | 0.84 | L3MBTL1 (0.40) | KDM4EBCHEACHEFFAR1L3MBTL1 | |
| SCHEMBL11994372 | 0.83 | FAAH (0.43) | L3MBTL1HTTSMN1; SMN2TRPV1MRGPRX4 | |
| SCHEMBL12878821 | 0.83 | EGFR (0.40) | KDM4EFFAR1L3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL24935379 | 0.81 | FFAR1 (0.40) | KDM4EBCHEACHEFFAR1PTGS1 | |
| SCHEMBL25063926 | 0.81 | KDM4E (0.42) | KDM4EBCHEACHEFFAR1SMN1; SMN2 | |
| SCHEMBL17811820 | 0.80 | L3MBTL1 (0.43) | KDM4EBCHEACHEL3MBTL1SMN1; SMN2 | |
| SCHEMBL20225798 | 0.80 | THRA (0.49) | L3MBTL1TRPV1MRGPRX4 | |
| SCHEMBL15000495 | 0.80 | THRA (0.49) | L3MBTL1TRPV1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | KDM4E 3001/4885BCHE 4817/4885ACHE 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.